

Background

- Acute pancreatitis (AP)** is an inflammatory disorder characterized by pancreatic injury and immune cell infiltration, which can often extend to other organs, such as the lungs.
- The inflammatory cascade** in AP involves the release of pro-inflammatory cytokines such as interleukin-1 β (IL-1 β), interleukin-6 (IL-6), and tumor necrosis factor- α (TNF- α), which drive immune cell infiltration, acinar cell injury, and multiorgan dysfunction.
- Mesenchymal stem cells (MSCs)** and their secreted products, particularly **extracellular vesicles (EVs)**, are being explored as therapeutic agents for inflammatory diseases.

Objectives

- Investigate the therapeutic effects of bone marrow MSC-derived EVs in a mouse model of cerulein-induced AP.
- Evaluate the ability of MSC-derived EVs to reduce inflammatory cytokine production and ceramide levels.
- Assess the ability of MSC-derived EVs to decrease immune cell infiltration, including neutrophils and macrophages.

Results




Fig. 1 Reduction of Cerulein-Induced Pancreatitis with Bone Marrow MSC-derived EVs. (A) NTA measured the size distribution of MSC-EVs. (B) Overview of the study design and timeline. (C) Pancreatic tissues harvested 48 hours post-induction of AP, with H&E staining; scale bar: 100 μ m. (D) Quantified histopathological scoring of pancreatic tissue. * $p < 0.05$, ** $p < 0.01$;




Fig. 2 MSC-derived EVs prevent proinflammatory cytokine production in AP. (A-C) Cytokine levels were measured with cytokine arrays from plasma obtained 48 hours after the first cerulein injection. MSC-EVs significantly reduced the expression of several proinflammatory genes (n = 3–6 per group). (D) Ceramide concentrations in the pancreas (n = 3 per group). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$

Conclusion

Administration of MSC-EVs reduces **cytokine-driven inflammation**, alters **sphingolipid metabolism**, and limits **immune cell infiltration** in a murine model of AP.

Our findings highlight the therapeutic potential of MSC-EVs as a cell-free, scalable, and effective treatment strategy for AP.

References

- Wei H, Chen F, Chen J, Lin H, Wang S, Wang Y, et al. Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis. *Int J Nanomedicine*. 2022;17:3483-95.
- He Z, Hua J, Qian D, Gong J, Lin S, Xu C, et al. Intravenous hMSCs Ameliorate Acute Pancreatitis in Mice via Secretion of Tumor Necrosis Factor- α Stimulated Gene/Protein 6. *Sci Rep*. 2016;6:38438.
- Chen G, Xu F, Li J, Lu S. Depletion of neutrophils protects against L-arginine-induced acute pancreatitis in mice. *Cell Physiol Biochem*. 2015;35(6):2111-20.




Fig. 4 MSC-derived EVs improve the infiltration of neutrophils and mast cells in AP. (A) Representative immunofluorescence images showing MPO expression in the pancreas and lung; scale bar: 25 μ m. Quantifying (B) MPO-positive pancreatic acinar and (C) lung cells in each group (n = 3–5 per group). ** $p < 0.01$, *** $p < 0.001$




Fig. 3 MSC-derived EVs modulate macrophage polarization in AP. (A) Immunofluorescence staining for CD206, CD11c, and CD68 in the pancreas; scale bar: 25 μ m. (B) Quantification of CD206/CD68-positive population in the pancreas. AP mice treated with MSC-EVs showed a non-significant increase in the proportion of CD206-positive cells (M2 macrophages) (n = 4 per group). (C) Quantification of CD11c/CD68-positive population in the pancreas. AP mice treated with MSC-EVs showed a significant decrease in the proportion of CD11c-positive cells (M1 macrophages) (n = 4 per group). ** $p < 0.01$, *** $p < 0.001$